Group | |||||
---|---|---|---|---|---|
Variable | S-CRT | S-RT | CRT | RT | p-Value |
n | 43 | 140 | 10 | 28 | - |
Age | |||||
Mean, yrs | 53.5 | 61.9 | 61.1 | 77.4 | <0.001* |
Range, yrs | 16.3 – 78.0 | 35.5 – 93.6 | 45.2 – 74.5 | 53.1 – 95.0 | |
Gender, no. (%) | 0.01* | ||||
Male | 21 (48.8) | 95 (67.9) | 6 (60.0) | 11 (39.3) | |
Female | 22 (51.2) | 45 (32.1) | 4 (40.0) | 17 (60.7) | |
Charlston Comorbidity Index, mean score (range) | 1.9 (0–9) | 2.3 (0–7) | 3.0 (0–7) | 5.4 (0–9) | <0.001* |
Site of tumor, no. (%) | |||||
Tongue, | 23 (53.5) | 51 (36.4) | 6 (60) | 8 (28.6) | 0.92 |
Floor of Mouth | 8 (18.6) | 37 (26.4) | 2 (20.0) | 7 (25.0) | |
Other | 12 (27.9) | 52 (37.1) | 2 (20) | 13 (46.4) | |
cT-stage, no. (%) | 0.16 | ||||
1 | 1 (2.3) | 9 (6.4) | 1 (10.0) | 0 (0.0) | |
2 | 15 (34.9) | 39 (27.9) | 2 (20.0 | 5 (17.8) | |
3 | 13 (30.2) | 28 (20.0) | 1 (10.0) | 4 (14.2) | |
4 | 14 (32.6) | 64 (45.7) | 6 (60.0) | 19 (67.8) | |
cN-stage, no. (%) | <0.001* | ||||
N0 | 2 (4.7) | 39 (27.9) | 2 (20.0) | 12 (42.9) | |
N1 | 4 (9.3) | 52 (37.1) | 3 (30.0) | 11 (39.3) | |
N2a | 3 (7.0) | 23 (16.4) | 2 (20.0) | 2 (7.1) | |
N2b | 18 (41.9) | 15 (10.7) | 2 (20.0) | 2 (7.1) | |
N2c | 14 (32.6) | 7 (5.0) | 0 (0.0) | 1 (3.6) | |
N3 | 2 (4.7) | 4 (2.9) | 1 (10.0) | 0 (0.0) | |
Perineural Invasion, no. (%) | 21 (48.8) | 34 (24.3) | / | / | 0.004* |
Lymph-vascular Invasion, no. (%) | 31 (72.1) | 24 (17.1) | / | / | <0.001* |
Extracapsular spread, no. (%) | 27 (62.8) | 46 (32.9) | / | / | 0.001* |
Overall stage, no. (%) | 0.60 | ||||
III | 4 (9.3) | 46 (32.9) | 0 (0) | 7 (25) | |
IV | 39 (90.7) | 94 (67.2) | 10 (100) | 21 (75) | |
Death, no. (%) | 17 (39.5) | 89 (63.6) | 10 (100) | 26 (92.9) | |
Death, cause (%) | 0.37 | ||||
Primary Cancer | 47.1 | 85.4 | 90 | 92.3 | |
Other Cancer | 23.5 | 5.6 | 0 | 3.8 | |
Non-Cancer | 29.4 | 10.1 | 10 | 11.5 |